Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials - PubMed (original) (raw)
Clinical Trial
Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials
G F Meadors 3rd et al. Vaccine. 1986 Sep.
Abstract
A formalin-inactivated Rift Valley fever vaccine prepared in primary monkey kidney cells has been used to protect laboratory workers from disease since 1967. A similar but improved vaccine was prepared in 1978-1979 using well characterized diploid fetal rhesus lung cells. In initial clinical trials reported here, the new vaccine elicited high levels of plaque neutralizing antibodies and caused only minimal local reactions at the injection site. Significant variability was observed in the geometric mean titre evoked by various vaccine lots. This variability had not been predicted by conventional pre-filtration or pre-inactivation virus infectivity assays, or the results of animal potency tests. These findings emphasize the need for statistically valid human potency testing and the development of accurate predictive preclinical measurements for this and other vaccines.
Similar articles
- A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up.
Kark JD, Aynor Y, Peters CJ. Kark JD, et al. Am J Epidemiol. 1982 Nov;116(5):808-20. doi: 10.1093/oxfordjournals.aje.a113471. Am J Epidemiol. 1982. PMID: 6890766 - Immune response of steers, goats and sheep to inactivated Rift Valley Fever vaccine.
Yedloutschnig RJ, Dardiri AH, Walker JS, Peters CJ, Eddy GA. Yedloutschnig RJ, et al. Proc Annu Meet U S Anim Health Assoc. 1979;(83):253-60. Proc Annu Meet U S Anim Health Assoc. 1979. PMID: 298921 No abstract available. - Rift Valley fever vaccine--antibody and immune response in cattle to a live and an inactivated vaccine.
Barnard BJ. Barnard BJ. J S Afr Vet Assoc. 1979 Sep;50(3):155-7. J S Afr Vet Assoc. 1979. PMID: 551199 - Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
Ikegami T. Ikegami T. Expert Rev Vaccines. 2017 Jun;16(6):601-611. doi: 10.1080/14760584.2017.1321482. Epub 2017 May 2. Expert Rev Vaccines. 2017. PMID: 28425834 Free PMC article. Review. - Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.
Terasaki K, Tercero BR, Makino S. Terasaki K, et al. Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27. Virus Res. 2016. PMID: 26022573 Free PMC article. Review.
Cited by
- An Overview of Rift Valley Fever Vaccine Development Strategies.
Kitandwe PK, McKay PF, Kaleebu P, Shattock RJ. Kitandwe PK, et al. Vaccines (Basel). 2022 Oct 25;10(11):1794. doi: 10.3390/vaccines10111794. Vaccines (Basel). 2022. PMID: 36366303 Free PMC article. Review. - Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses.
Harmon JR, Barbeau DJ, Nichol ST, Spiropoulou CF, McElroy AK. Harmon JR, et al. NPJ Vaccines. 2020 Feb 28;5(1):17. doi: 10.1038/s41541-020-0166-9. eCollection 2020. NPJ Vaccines. 2020. PMID: 32140261 Free PMC article. - An equine herpesvirus type 1 (EHV-1) vector expressing Rift Valley fever virus (RVFV) Gn and Gc induces neutralizing antibodies in sheep.
Said A, Elmanzalawy M, Ma G, Damiani AM, Osterrieder N. Said A, et al. Virol J. 2017 Aug 14;14(1):154. doi: 10.1186/s12985-017-0811-8. Virol J. 2017. PMID: 28807043 Free PMC article. - Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.
Pittman PR, Norris SL, Brown ES, Ranadive MV, Schibly BA, Bettinger GE, Lokugamage N, Korman L, Morrill JC, Peters CJ. Pittman PR, et al. Vaccine. 2016 Jan 20;34(4):523-530. doi: 10.1016/j.vaccine.2015.11.078. Epub 2015 Dec 17. Vaccine. 2016. PMID: 26706271 Free PMC article. Clinical Trial. - Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya.
LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ, Traylor Z, Gildengorin G, Muchiri EM, Morrill J, Peters CJ, Hise AG, Kazura JW, King CH. LaBeaud AD, et al. PLoS Negl Trop Dis. 2015 Mar 12;9(3):e0003548. doi: 10.1371/journal.pntd.0003548. eCollection 2015 Mar. PLoS Negl Trop Dis. 2015. PMID: 25764399 Free PMC article.